AngioVac F1885
AngioDynamics, Inc. · Decision date Oct 30, 2026
What did the FDA decide?
The FDA's device database records K263076 for the AngioVac F1885, submitted by AngioDynamics, Inc. of Queensbury, New York. The entry lists the review specialty as cardiovascular and the product code as DWF, with a decision date of 30 October 2026 and a decision code of SESE. The record also shows a traditional review track, no third-party review, and a summary as the review advisory committee statement type. The source does not describe the specific component, modification, or intended change associated with this submission.
SESE denotes a 510(k) substantial-equivalence clearance rather than premarket approval of a new device. The record does not identify a predicate device, so the application relationship to prior cleared devices remains unknown. The listed title, AngioVac F1885, is the only device descriptor available here; indications, materials, and performance data are not included. Researchers should treat this as a clearance record only and consult the corresponding FDA 510(k) documents for scope and any clinical claims.
The source data are limited to a summary listing row, and no statement text was provided. Missing items include the device description, the changed or added component, and any comparison to a predicate. No efficacy, safety, or patient-selection conclusions can be drawn from this record.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 30, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K263076
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- AngioDynamics, Inc.
- Product code
- DWF
- Decision code
- SESE
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass.
- Applicant
- AngioDynamics, Inc.
- Product code
- DWF
- FDA device class
- 2
FDA decision timeline
K263076 received
Application receipt date recorded by FDA.
K263076 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code DWF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
DLP Coronary Ostial CannulaeK263596 | Medtronic, Inc. | 510(k) clearance | Oct 29, 2026 | FDA |
Dual Stage Venous CannulaeK263092 | Sorin Group Italia S.R.L. | 510(k) clearance | Oct 1, 2026 | FDA |
Tri Stage Venous CannulaeK262052 | Sorin Group Italia S.R.L. | 510(k) clearance | Sep 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
AngioDynamics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Queensbury, NY
Sources and methodology
- Original FDA record: K263076
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

